Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081678 · ClinicalTrials.gov registry record · Phase 2
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
NCT01081678 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 332 participants.
The verdict
NCT01081678, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
Study Summary
This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.
Interventions
- DRUG Placebo
- DRUG Romosozumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2010-06-20 |
| Est. Completion | 2013-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01081678
The ClinicalTrials.gov registry entry for NCT01081678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01081678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01081678 about?
NCT01081678 is a clinical study titled "Study To Assess FRacTure Healing With SclerosTin Antibody - Hip". This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.
What is the current status of trial NCT01081678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2010-06-20. Estimated completion is 2013-05-10.
What interventions are being tested in trial NCT01081678?
The interventions under investigation include: Placebo (DRUG), Romosozumab (DRUG).
Who is sponsoring clinical trial NCT01081678?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.